Cargando…
Amelioration of diet-induced steatohepatitis in mice following combined therapy with ASO-Fsp27 and fenofibrate
Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease. NAFLD progresses from benign steatosis to steatohepatitis (NASH) to cirrhosis and is linked to hepatocellular carcinoma. No targeted treatment is currently approved for NAFLD/NASH. We previously showed that fat-s...
Autores principales: | Rajamoorthi, Ananthi, Arias, Noemí, Basta, Jeannine, Lee, Richard G., Baldán, Ángel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society for Biochemistry and Molecular Biology
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5665668/ https://www.ncbi.nlm.nih.gov/pubmed/28874443 http://dx.doi.org/10.1194/jlr.M077941 |
Ejemplares similares
-
Therapeutic silencing of FSP27 reduces the progression of atherosclerosis in Ldlr(−/−) mice
por: Rajamoorthi, Ananthi, et al.
Publicado: (2018) -
Therapeutic silencing of fat-specific protein 27 improves glycemic control in mouse models of obesity and insulin resistance
por: Langhi, Cédric, et al.
Publicado: (2017) -
Gene expression profile in the fat tissue of Fsp27 deficient mice
por: Xu, Li, et al.
Publicado: (2015) -
Lipid droplets fatten up with Fsp27
por: Short, Ben
Publicado: (2011) -
Fenofibrate Ameliorated Systemic and Retinal Inflammation and Modulated Gut Microbiota in High-Fat Diet-Induced Mice
por: Wang, Xue, et al.
Publicado: (2022)